Key Market Insights
With six approved therapies and over 970 preclinical / clinical product candidates, CAR-T cell therapies represent the most active segment of the pharmaceutical domain
More than 80% of the therapy candidates, which are being developed to target a range of disease indications, are autologous in nature; CD19 and BCMA have emerged as the most popular target antigens
Several scientists from renowned universities are presently involved in clinical development efforts of CAR T cell therapies; these KOLs are primarily based in the US and China
Specifically, for CAR-T cell therapies, extensive efforts are underway to improve the CAR constructs across successive generations, involving alterations in the scFv region and using different types of gene delivery vectors
In the last 10 years, over 750 clinical trials have been registered across different geographies for CAR-T cell therapies; extensive efforts are underway to improve successive generations of therapies
Close to 200 players claim to have the required capabilities to manufacture different types of cell therapies; such firms also offer a wide range of services across different stages of product development
A rise in partnerships, in the recent past, involving both international and indigenous stakeholders, validate the growing interest in this domain; maximum number of such deals were signed in 2021
Several investors, having realized the opportunity within this upcoming segment of cancer immunotherapy, have invested USD 25 billion, across 260+ instances, during the period 2000-2022
More than 6,500 patents have been granted / filed for CAR-T cell therapies, primarily led by the non-industry players
With a growing focus on the development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of over 20%, during the next decade
The projected opportunity within the CAR T cell therapy market is expected to be well distributed across key / emerging players and different geographical regions
Table of Contents
1. . PREFACE
1.1. Scope of the Report
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapies
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapy
3.6. T-Cell Immunotherapies
3.7. Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
3.8. Concluding Remarks
4. CAR-T CELL THERAPIES: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. CAR-T Cell Therapies: Overall Market Landscape
4.3. CAR-T Cell Therapies: Overall Developer Landscape
5. KEY INSIGHTS
5.1. Chapter Overview
5.2. CAR-T Cell Therapies: Competitive Analysis of Popular Target Antigens
5.3. CAR-T Cell Immunotherapies: CAR Construct Analysis
6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. CAR-T Cell Therapies: Clinical Trial Analysis
7. KEY OPINION LEADERS
7.1. Chapter Overview
7.2. Assumptions and Key Parameters
7.3. Methodology
7.4. CAR-T Cell Therapies: Key Opinion Leaders
8. CAR-T CELL THERAPY PROFILES
8.1. Chapter Overview
8.2. Kymriah / Tisagenlecleucel / CTL019 (Novartis)
8.3. Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences)
8.4. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
8.5. Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb)
8.6. Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb)
8.7. Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen)
8.8. Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics)
8.9. TBI-1501 / CD19 CAR-T Cell Therapy (Takara Bio)
8.10. AUTO1 / Obecabtagene Autoleucel / obe-cel (Autolus)
8.11. AUTO3 / CD19/22 CAR-T (Autolus)
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. CAR-T Cell Therapies: Partnerships and Collaborations
10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. CAR-T Cell Therapies: Funding and Investment Analysis
11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. CAR-T Cell Therapies: Patent Analysis
12. CASE STUDY: CELL THERAPY MANUFACTURING
12.1. Chapter Overview
12.2. Overview of Cell Therapy Manufacturing
12.3. Cell Therapy Manufacturing Models
12.4. Scalability of Cell Therapy Manufacturing Processes
12.5. Types of Cell Therapy Manufacturers
12.6. Key Challenges Related to Manufacturing of Cell Therapies
12.7. Key Considerations for Cell Therapy Manufacturing
12.8. Automation of Cell Therapy Manufacturing Process
12.9. Cell Therapy Manufacturing Supply Chain
12.10. Comparison of Players Having In-House Capabilities and Contract Manufacturers
12.11. Regulatory Landscape
12.12. Future Perspectives
13. COST PRICE ANALYSIS
13.1. Chapter Overview
13.2. Factors Contributing to the High Price of Cell / Gene Therapies
13.3. Pricing Models for T-Cell Immunotherapies
13.4. Reimbursement related Considerations for T-cell Immunotherapies
14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Scope and Limitations
14.3. Key Assumptions and Forecast Methodology
14.4. Global CAR-T Cell Therapies Market, 2022-2035
15. PROMOTIONAL ANALYSIS
15.1. Chapter Overview
15.2. Channels Used for Promotional Campaigns
15.3. Summary of Product Website Analysis
15.4. Summary of Patient Support Services and Informative Downloads
15.5. Kymriah: Promotional Analysis
15.6. Yescarta: Promotional Analysis
15.7. Tecartus: Promotional Analysis
15.8. Breyanzi: Promotional Analysis
15.9. Abecma: Promotional Analysis
15.10. Carvykti: Promotional Analysis
16. COMPANY PROFILES
16.1. Chapter Overview
16.2. Alaunos Therapeutics
16.3. Autolus
16.4. Bluebird Bio
16.5. Bristol Myers Squibb
16.6. Carsgen Therapeutics
16.7. Cellectis
16.8. Cellular Biomedicine Group
16.9. Gilead Sciences
16.10. Innovative Cellular Therapeutics
16.11. Kuur Therapeutics
16.12. Noile-Immune Biotech
16.13. Novartis
16.14. Shanghai GeneChem
16.15. Sinobioway Cell Therapy
16.16. Takara Bio
16.17. Wellington Zhaotai Therapies
17. CONCLUDING REMARKS
18. EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. Glycostem Therapeutics
18.3. TxCell
18.4. Kite Pharma
18.5. Celyad
18.6. Waisman Biomanufacturing
18.7. Theravectys
18.8. Changhai Hospital
18.9. University of Colorado
19. APPENDIX 1: TABULATED DATA
